# Next-Generation Oral SERD Approved for Breast Cancer

Source: [MedPageToday.com - medical news for physicians](https://www.medpagetoday.com/hematologyoncology/breastcancer/123915) · 2026-11-17 · Medicine
Page: https://themorning.science/story/next-generation-oral-serd-approved-for-breast-cancer-1e75f31443c4e6e0
Kind: launch · Impact: medium

## In brief

- The FDA approved giredestrant (brand name Wilserdly) in combination with everolimus.
- The approval covers previously treated ER-positive, HER2-negative, ESR1-mutated breast cancer.
- Giredestrant is described as a next-generation oral selective estrogen receptor degrader (SERD).

## Why it matters

It adds an oral treatment option for a subset of previously treated, ESR1-mutated, ER-positive breast cancer, which matters for oncologists choosing second-line therapy.

## Timeline

- 2026-11-17: FDA approves giredestrant (Wilserdly) with everolimus

## Coverage

- [Next-Generation Oral SERD Approved for Breast Cancer](https://www.medpagetoday.com/hematologyoncology/breastcancer/123915) — MedPageToday.com - medical news for physicians, 2026-11-17

Tags: breast cancer, fda approval, oral serd, giredestrant, oncology

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
